Eyenuk
Woodland Hills, US · Founded 2013 · Delaware corporation · 1 known investors
Eyenuk provides autonomous AI-based eye exams performed at the point of care to detect eye conditions including diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucomatous signs. Its technology holds regulatory clearances such as a Class IIb CE mark under EU MDR and maintains SOC 2 Type 2, HIPAA, and GDPR compliance.
Founders & leadership
Investors · 1
Competitors · 7
by search overlapCompanies competing with Eyenuk for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$5.6MraisedJun 2026 · 12 investors · Other Health CareRule 506(b)
- Gaurav AgarwalExecutive Officer, Director
- Mads DallDirector
- Zina Affas BesseDirector
- Marie-Louise LittleDirector
- Kaushal SolankiDirector
- Offering amount
- $5.6M
- Amount sold
- $5.6M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.4MraisedAug 2022 · 27 investors · Other Health CareRule 506(b)
- Frank ChengExecutive Officer
- Zina Affas BesseDirector
- Kaushal SolankiExecutive Officer, Director
- Marie-Louise LittleDirector
- Manish PottiDirector
- Robert BinneyDirector
- Offering amount
- $26.9M
- Amount sold
- $22.4M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMay 2018 · 6 investors · Other Health CareRule 506(b)
- Martin CoyneDirector
- Kaushal SolankiExecutive Officer, Director
- Manish PottiDirector
- Offering amount
- $4M
- Amount sold
- $3M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$1.4MraisedNov 2017 · 8 investors · Other Health CareRule 506(b)
- Manish PottiDirector
- Martin CoyneDirector
- Kaushal SolankiExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.4M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$1.5MraisedJul 2016 · 7 investors · Other Health CareRule 506(b)
- Kaushal SolankiExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $1.5M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 15 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $218.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $216.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $788.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $217K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $399.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $260.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
